Business Context and Reporting Period
Company: Calidi Biotherapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: December 13, 2023
Reporting Period: Event-based report regarding a presentation delivered on December 13, 2023.
The Company is an emerging growth company incorporated in Delaware. It operates in the biotechnology sector, focusing on allogeneic stem cell-based virotherapy platforms.
Key Financial Metrics
This filing is a Regulation FD disclosure regarding a corporate presentation and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
No material financial changes or operational updates were reported in this specific filing. The document serves solely to disclose the furnishing of a presentation to the public.
Guidance, Outlook, and Management Commentary
Event: On December 13, 2023, the Company presented its NeuroNova and SuperNova allogeneic stem cell-based virotherapy platforms at the 8th Oncolytic Virotherapy Summit in Boston, Massachusetts.
Legal Status of Information: The information contained in the presentation (Exhibit 99.1) is "furnished" and not "filed" for purposes of Section 18 of the Securities Exchange Act of 1934. It is not subject to the liabilities of that section and shall not be deemed incorporated by reference in any other filing.
Investor Verification Checklist
- Review Exhibit 99.1 (the attached presentation) for specific details on the NeuroNova and SuperNova platforms.
- Verify the Company's status as an emerging growth company and its implications for financial reporting.
- Check subsequent filings (e.g., 10-K or 10-Q) for actual financial performance data, as this 8-K contains no financial metrics.
- Confirm the trading symbols: Common Stock (CLDI) and Redeemable Warrants (CLDIWS) on NYSE American LLC.